Home
Service
Small Molecule Services
Macromolecular Services
In vitro ADME Screening Services
Animal Experimental Services
Daily Chemical Testing Service
Our Clients
COOPERATION CUSTOMERS
Apply immediately
Articles
Article published
Academic research
Guarantee
Quality Assurance
Organizational guarantee
Process assurance
Information Assurance
Technical support
News
Guochen Dynamic
Industry News
About Us
Company Profile
Enterprise culture
Development process
Contact Us
Over 3 billion yuan! Corning Jerry and Shiyao Group Reach Cooperation on HER2 Dual-level ADC
On September 29, Corning Jerry announced that it has entered into a license agreement ("License Agreement") with Zimant Biotechnology, a wholly-owned subsidiary of CSPC, to develop, sell, promise to sell and commercialize JSKN003 (a HER2-targeted dual-site ADC) in mainland China (excluding Hong Kong, Macau or Taiwan) for the treatment of cancer-related indications.
29
2024
/
09
This local medical device company's profit in the first quarter exceeded 3.1 billion! Mindray, Xinhua, and United Imaging ranked in the top three, while GE, Philips, and Siemens lost momentum
Recently, the first quarter reports of major domestic medical device companies have all been released. The New Media Center of "Pharmaceutical Economic News" has comprehensively sorted out the financial report data of the top 5 medical device companies. Among them, Mindray Medical, Xinhua Medical, United Imaging Healthcare, Yuyue Medical, and Intech Medical have revenues exceeding 2 billion yuan; if ranked by R&D investment, Mindray Medical, United Imaging Healthcare, Neusoft Medical, Lepu Medical, and Yuyue Medical rank high, and their R&D investment has exceeded 100 million yuan.
25
05
Eli Lilly buys an injection factory! GLP-1 production capacity "ceiling", putting pressure on Novo Nordisk?
Recently, Eli Lilly announced that it had reached a final agreement with sterile drug manufacturer Nexus Pharmaceuticals to acquire the latter's injectable drug manufacturing plant in Pleasant Prairie, Wisconsin, USA. Eli Lilly believes that this acquisition will further expand its global manufacturing network for injectable products and support the market's increased demand for the company's related drugs. Eli Lilly estimates that the plant may begin production by the end of 2025.
27
04
Analysis of the registration key points of biosynthetic and traditional microbial fermentation APIs
Synthetic biology can be understood as the engineering of biology, which is equivalent to deconstructing various basic biological components and then reconstructing biological systems with desired functions to produce various target substances. McKinsey predicts that by 2025, the economic value of synthetic biology and biomanufacturing may reach as high as 100 billion US dollars, and 60% of global material production in the future can be achieved through synthetic biology manufacturing. As a cutting-edge interdisciplinary subject, the scope of application of synthetic biology basically covers most fields, and has broad application prospects in the fields of medicine, health, manufacturing, agriculture, etc.
26
Leading the nuclear medicine track, opening the road of RLT commitment to China
Innovative drug research and development involves multiple fields and links, including efficacy, pharmacokinetic, safety evaluation, clinical, etc. Each link has its own special requirements and challenges. To improve R&D efficiency and quality and accelerate the process of listing, non-clinical and translational medicine research plays a vital role in biopharmaceutical R&D.
16
General considerations for ADC clinical dose optimization
In recent years, dose optimization has become a key focus of the FDA when reviewing new oncology drugs.
24
$9 billion! Eli Lilly invests to expand telportipad production capacity
On May 24, Eli Lilly announced that its investment in its Lebanon, Indiana manufacturing site has more than doubled, with a new investment of $5.3 billion, bringing the company's total investment in the manufacturing site from $3.7 billion to $9 billion. The expansion will increase Eli Lilly's ability to produce tirpotide, Zepbound injection, and Mounjaro injection active pharmaceutical ingredients (API), so that more patients with chronic diseases such as obesity and type 2 diabetes can benefit from it.
China's King of Medicine vs. World's King of Medicine "Sales TOP List"
The world's leading drug in 2023 is Merck's oncology antibody therapy Keytruda, with annual sales reaching US$25 billion, a year-on-year increase of nearly 20%.
